#1 Clinical Trials Search in Europe

Abc-16F-116

Recent clinical trials are investigating the V116 pneumococcal vaccine, a 21-valent conjugate vaccine developed by Merck & Co. Inc. These studies aim to assess the safety, tolerability, and immune response of V116 in various populations at increased risk for pneumococcal disease, including adults, children, and adolescents. The trials compare V116 to existing pneumococcal vaccines and evaluate its potential in preventing pneumococcal infections.

Table of Contents

What is ABC-16F-116?

ABC-16F-116 is one of the components of a new pneumococcal vaccine called V116 that is currently being developed and tested[1]. V116 is a 21-valent pneumococcal conjugate vaccine, which means it targets 21 different strains or serotypes of pneumococcal bacteria[2]. This vaccine is being created to help prevent pneumococcal disease, a serious infection caused by Streptococcus pneumoniae bacteria.

Purpose of ABC-16F-116

The main purpose of ABC-16F-116, as part of the V116 vaccine, is to prevent pneumococcal infections. These infections can range from mild illnesses like ear infections to more severe and potentially life-threatening conditions such as pneumonia, meningitis, and bloodstream infections (sepsis)[1][2]. By including ABC-16F-116 and other components, the V116 vaccine aims to provide broader protection against various pneumococcal strains.

How ABC-16F-116 Works

ABC-16F-116 is a conjugate vaccine, which means it combines a specific part of the pneumococcal bacteria (in this case, likely from serotype 16F) with a carrier protein called CRM197[1]. This combination helps to enhance the immune response, especially in young children. When a person receives the vaccine, their immune system recognizes these bacterial components and develops antibodies against them. If the person later encounters the real pneumococcal bacteria, their immune system is prepared to fight off the infection more effectively.

Clinical Trials

The V116 vaccine, which includes ABC-16F-116, is currently undergoing Phase 3 clinical trials. These trials are designed to evaluate the safety, tolerability, and effectiveness of the vaccine in different populations[1][2][3]. The studies are assessing various aspects, including:

  • The vaccine’s ability to stimulate an immune response (immunogenicity)
  • The occurrence of side effects or adverse events
  • How well it performs compared to existing pneumococcal vaccines

Target Population

The clinical trials for V116 (including ABC-16F-116) are focusing on several groups of people:

  • Adults aged 18 to 64 years who are at increased risk for pneumococcal disease[1]
  • Adults aged 50 years and older[2]
  • Children and adolescents with increased risk of pneumococcal disease[3]

These groups are considered to be at higher risk for serious pneumococcal infections due to factors such as age, certain medical conditions, or weakened immune systems.

Administration

Based on the clinical trial information, V116 (which includes ABC-16F-116) is administered as an intramuscular injection. The vaccine is given as a single 0.5 ml dose[1][2][3]. This means it’s injected directly into a muscle, typically in the upper arm or thigh.

Safety and Side Effects

One of the main objectives of the ongoing clinical trials is to assess the safety and tolerability of V116, including the ABC-16F-116 component. Researchers are carefully monitoring for any adverse events (side effects) that may occur after vaccination. Common side effects of vaccines can include pain at the injection site, fatigue, headache, and mild fever. However, the specific side effect profile for V116 will be determined once the clinical trials are completed and the data is analyzed[1][2][3].

Potential Benefits

If proven safe and effective, V116 (including ABC-16F-116) could offer several potential benefits:

  • Broader protection against pneumococcal infections due to its 21-valent formulation
  • Reduced risk of serious pneumococcal diseases like pneumonia, meningitis, and sepsis
  • Improved immune response in populations at higher risk for pneumococcal disease
  • Potential to prevent antibiotic-resistant pneumococcal infections

It’s important to note that while ABC-16F-116 shows promise as part of the V116 vaccine, it is still under investigation. The full benefits and any limitations will be better understood once all clinical trial data has been collected and analyzed[1][2][3].

Aspect Details
Vaccine Name V116 (Pneumococcal 21-valent Conjugate Vaccine)
Manufacturer Merck & Co. Inc.
Study Populations Adults 18-64 years, Adults 50+ years, Children and adolescents at increased risk
Primary Objectives Safety, tolerability, immunogenicity compared to existing vaccines
Administration 0.5 ml intramuscular injection
Key Measurements Adverse events, OPA GMTs, IgG GMCs, proportion with ≥4-fold antibody rise
Comparison Vaccine PPSV23 (23-valent pneumococcal polysaccharide vaccine)
Risk Conditions Studied Diabetes, chronic liver/lung/heart/kidney disease

FAQ

  • What is V116? V116 is a 21-valent pneumococcal conjugate vaccine developed by Merck & Co. Inc. It is designed to protect against various strains of pneumococcal bacteria that can cause serious infections.
  • Who is being studied in these clinical trials? The clinical trials are studying different groups at increased risk for pneumococcal disease, including adults aged 18-64, adults 50 years and older, and children and adolescents with certain medical conditions that increase their risk of pneumococcal infections.
  • What are the main objectives of these trials? The main objectives are to evaluate the safety and tolerability of V116, as well as its ability to stimulate an immune response (immunogenicity) compared to existing pneumococcal vaccines like PPSV23.
  • How is the vaccine administered? V116 is administered as an intramuscular injection, with a dose of 0.5 ml.
  • What are some of the medical conditions that put people at higher risk for pneumococcal disease? Some conditions that increase risk include diabetes mellitus, chronic liver disease, chronic lung disease (such as COPD or asthma), chronic heart disease, and chronic kidney disease.

Ongoing Clinical Trials on Abc-16F-116

  • Study on the Safety and Immune Response of V116 Vaccine for Pneumococcal Disease in Adults Aged 50 and Older

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Germany Spain

  • Study on the Safety and Immune Response of V116 Vaccine in Children and Adolescents at Higher Risk for Pneumococcal Disease

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Finland France Poland Spain Sweden

  • Study on the V116 Vaccine for Adults Aged 18-64 at Increased Risk of Pneumococcal Infection

    Not recruiting

    3 1 1
    Investigated drugs:
    Poland

Glossary

  • Pneumococcal disease: Infections caused by Streptococcus pneumoniae bacteria, which can lead to serious illnesses like pneumonia, meningitis, and bloodstream infections.
  • Conjugate vaccine: A type of vaccine that joins a weak antigen to a strong antigen to improve the immune response, especially in young children.
  • Opsonophagocytic activity (OPA): A measure of antibody function that indicates how well antibodies help immune cells engulf and destroy bacteria.
  • Immunoglobulin G (IgG): The most common type of antibody in blood that helps protect against bacterial and viral infections.
  • Geometric mean titer (GMT): A way to measure the average amount of antibodies in a group of people, useful for comparing immune responses.
  • Adverse event (AE): Any unfavorable or unintended sign, symptom, or disease that occurs during a clinical trial, whether or not it's related to the treatment being studied.
  • Serotype: A distinct variation within a species of bacteria, in this case, different strains of pneumococcal bacteria.
  • PPSV23: Pneumococcal polysaccharide vaccine, a 23-valent vaccine used to prevent pneumococcal infections in adults and some children.

References

  1. http://clinicaltrials.eu/trial/study-on-the-v116-vaccine-for-adults-aged-18-64-at-increased-risk-of-pneumococcal-infection/
  2. http://clinicaltrials.eu/trial-id/2022-503144-40-00
  3. http://clinicaltrials.eu/trial/study-on-the-safety-and-immune-response-of-v116-vaccine-in-children-and-adolescents-at-higher-risk-for-pneumococcal-disease/